WHAT IS CLAIMED IS:

1. A compound of the formula (I):



(I)

wherein: **X** is $-CHR_3-$, $-CHR_3$-alkyl-, or $-CHR_3$-alkenyl-;

$\mathbf{R_1}$ is selected from the group consisting of:

-heteroaryl;

-heterocyclyl;

$-R_4-$ heteroaryl; and

$-R_4-$heterocyclyl;

$\mathbf{R_2}$ is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkyl-Y-alkyl;

-alkyl-Y- alkenyl;

-alkyl-Y-aryl; and

- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

-halogen;

-$N(R_3)_2$;
-CO-$N(R_3)_2$;
-CO-C_{1-10} alkyl;
-CO-O-C_{1-10} alkyl;
-N_3;
-aryl;
-heteroaryl;
-heterocyclyl;
-CO-aryl; and
-CO-heteroaryl;

R_4 is alkyl or alkenyl, which may be interrupted by one or more –O– groups;
each R_3 is independently H or C_{1-10} alkyl;
each Y is independently –O– or $-S(O)_{0-2}$-;
n is 0 to 4; and
each R present is independently selected from the group consisting of C_{1-10} alkyl, C_{1-10} alkoxy, hydroxy, halogen and trifluoromethyl;
or a pharmaceutically acceptable salt thereof.

2. A compound or salt of claim 1 wherein R_1 is $-(CH_2)_{0-3}$–heteroaryl.

3. A compound or salt of claim 2 wherein the heteroaryl is selected from the group consisting of 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-thiazolyl, 2-pyrimidinyl, 4-pyrimidinyl, 4-triazolyl, 2-benzofuranyl, 2-indolyl, 3-carbazolyl, 2-furanyl, 4-isoquinolinyl, 4-isoxazolyl, and 4-pyrazolyl

4. A compound or salt of claim 1 wherein X is –CH(alkyl)(alkyl)– wherein the alkyl groups can be the same or different.

5. A compound or salt of claim 1 wherein X is $–CH_2–CH_2–$.

6. A compound or salt of claim 1 wherein X is $-CH(C_2H_5)(CH_2)-$.

7. A compound or salt of claim 1 wherein R_2 is H.

8. A compound or salt of claim 1 wherein R_2 is alkyl.

9. A compound or salt of claim 1 wherein R_2 is –alkyl–O–alkyl.

10. A compound of the formula (II)



(II)

wherein: **X** is $-CHR_3-$, $-CHR_3$-alkyl-, or $-CHR_3$-alkenyl-;

$\mathbf{R_{10}}$ is selected from the group consisting of heteroaryl and heterocyclyl;

$\mathbf{R_2}$ is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkyl-Y-alkyl;

-alkyl-Y- alkenyl;

-alkyl-Y-aryl; and

-alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;
-halogen;
$-N(R_3)_2$;
$-CO-N(R_3)_2$;
$-CO-C_{1-10}$ alkyl;
$-CO-O-C_{1-10}$ alkyl;
$-N_3$;
-aryl;
-heteroaryl;
-heterocyclyl;
-CO-aryl; and
-CO-heteroaryl;

n is 0 to 4;

each R_3 is independently H or C_{1-10} alkyl;

each **Y** is independently –O– or $-S(O)_{0-2}$-; and

each **R** present is independently selected from the group consisting of C_{1-10} alkyl, C_{1-10} alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof.

11. A compound or salt of claim 10 wherein R_{10} is selected from the group consisting of heteroaryl and substituted heteroaryl.

12. A compound of claim 11 wherein the heteroaryl is selected from the group consisting of 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-thiazolyl, 4-pyrazolyl, 3-furanyl, 2-thienyl, and 2-pyrimidinyl.

13. A compound or salt of claim 10 wherein X is –CH(alkyl)(alkyl)–, wherein the alkyl groups can be the same or different.

14. A compound or salt of claim 10 wherein X is $-CH_2-CH_2-$.

15. A compound or salt of claim 10 wherein X is $-CH(C_2H_5)(CH_2)-$.

16. A compound or salt of claim 10 wherein R_2 is H, alkyl, or alkyl-O-alkyl.

17. A compound selected from the group consisting of:

1-(2-{[3-(isoquinolin-4-yl)-2-propynyl]oxy}ethyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-(2-{[3-(1,3-thiazol-2-yl)-2-propynyl]oxy}ethyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-{2-[3-(1*H*-4-pyrazolyl)propoxy]ethyl}-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-[2-(3-pyrimidin-2-ylpropoxy)ethyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-[2-(3-pyridin-4-ylpropoxy)ethyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-[2-(3-pyridin-2-ylpropoxy)ethyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-{2-[3-(1,3-thiazol-2-yl)propoxy]ethyl}-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-[2-(3-pyridin-3-ylpropoxy)ethyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-[2-(3-pyrimidin-5-ylpropoxy)ethyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-{2-[(1-benzyl-1*H*-1,2,3-triazol-4-yl)methoxy]ethyl}-1*H*-imidazo[4,5-*c*]quinoline-4-amine;

1-{2-[(1-benzyl-1*H*-1,2,3-triazol-5-yl)methoxy]ethyl}-1*H*-imidazo[4,5-*c*]quinoline-4-amine;

1-[2-({1-[(phenylsulfanyl)methyl]-1*H*-1,2,3-triazol-4-yl}methoxy)ethyl]-1*H*-imidazo[4,5-*c*]quinoline-4-amine;

1-[2-({1-[(phenylsulfanyl)methyl]-1*H*-1,2,3-triazol-5-yl}methoxy)ethyl]-1*H*-imidazo[4,5-*c*]quinoline-4-amine;

1-[2-(benzo[b]furan-2-ylmethoxy)ethyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-[2-(pyridin-3-ylmethoxy)ethyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-[2-(pyridin-2-ylmethoxy)ethyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-[2-(pyridin-4-ylmethoxy)ethyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-{2-[(3,5-dimethylisoxazol-4-yl)methoxy]ethyl}-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-(2-{[3-(pyrimidin-2-yl)-2-propynyl]oxy}ethyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-(2-{[3-(pyrid-4-yl)-2-propynyl]oxy}ethyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine;
1-(2-{[3-(fur-3-yl)-2-propynyl]oxy}ethyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine;
4-{3-[2-(4-amino-1*H*-imidazo[4,5-*c*]quinolin-1-yl)ethoxy]-propyn-1-yl}
thiophen-2-ylcarboxaldehyde;
1-(2-{[3-(pyrid-2-yl)-2-propynyl]oxy}ethyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine;
1-{2-methyl-1-[(pyrid-2-yloxy)methyl]propyl}-1*H*-imidazo[4,5-*c*]quinoline-4-
amine;
1-{1-[(pyrid-2-yloxy)methyl]propyl}-1*H*-imidazo[4,5-*c*]quinoline-4-amine;
1-[2-(9*H*-carbazol-3-yloxy)propyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;
1-{2-[(3-thien-2-ylprop-2-ynyl)oxy]ethyl}-1*H*-imidazo[4,5-*c*]quinolin-4-amine;
1-{2-[(1-methyl-1*H*-indol-2-yl)methoxy]ethyl}-1*H*-imidazo[4,5-*c*]quinolin-4-
amine;
1-[2-(3-thien-2-ylpropoxy)ethyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;
2-methyl-1-[2-(3-pyridin-3-ylpropoxy)ethyl]-1*H*-imidazo[4,5-*c*]quinoline-4-amine;
2-butyl-1-[2-(3-pyridin-3-ylpropoxy)ethyl]-1*H*-imidazo[4,5-*c*]quinoline-4-amine;
1-[2-(tetrahydrofuran-2-ylmethoxy)propyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;
1-{2-[(5-chloro-1-benzothien-3-yl)methoxy]propyl}-1*H*-imidazo[4,5-*c*]quinolin-4-
amine;
1-{2-[(3-nitropyridin-2-yl)oxy]propyl}-1*H*-imidazo[4,5-*c*]quinolin-4-amine;
1-(2-methyl-1-{[(3-nitropyridin-2-yl)oxy]methyl}propyl)-1*H*-imidazo[4,5-
c]quinolin-4-amine;
1-(1-{[(5-chloro-1-benzothien-3-yl)methoxy]methyl}-2-methylpropyl)-1*H*-
imidazo[4,5-*c*]quinolin-4-amine;
2-(2-methoxyethyl)-1-[2-(3-pyridin-3-ylpropoxy)ethyl]-1*H*-imidazo[4,5-
c]quinolin-4-amine; and
2-methyl-1-[2-(3-pyridin-3-ylpropoxy)ethyl]-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-
c]quinolin-4-amine;

or a pharmaceutically acceptable salt thereof.

18. A compound of the formula (III)



(III)

wherein: **X** is $-CHR_3-$, $-CHR_3$-alkyl-, or $-CHR_3$-alkenyl-;

$\mathbf{R_1}$ is selected from the group consisting of:

-heteroaryl;

-heterocyclyl;

$-R_4-$ heteroaryl; and

$-R_4-$heterocyclyl;

$\mathbf{R_2}$ is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkyl-Y-alkyl;

-alkyl-Y- alkenyl;

-alkyl-Y-aryl; and

- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

-halogen;

$-N(R_3)_2$;

$-CO-N(R_3)_2$;

-CO-C_{1-10} alkyl;

-CO-O-C_{1-10} alkyl;

-N_3;

-aryl;

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

R_4 is alkyl or alkenyl, which may be interrupted by one or more –O– groups;

each R_3 is independently H or C_{1-10} alkyl;

each Y is independently –O– or $-S(O)_{0-2}$-;

n is 0 to 4; and

each R present is independently selected from the group consisting of C_{1-10} alkyl, C_{1-10} alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof.

19. A compound or salt of claim 18 wherein R_2 is H or alkyl.

20. A compound or salt of claim 18 wherein R_2 is –alkyl–O–alkyl.

21. A compound of the formula (IV):



(IV)

wherein: X is $-CHR_3$-, $-CHR_3$-alkyl-, or $-CHR_3$-alkenyl-;

R_{10} is selected from the group consisting of heteroaryl and heterocyclyl;

R_2 is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkyl-Y-alkyl;

-alkyl-Y-alkenyl;

-alkyl-Y-aryl; and

-alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

-halogen;

$-N(R_3)_2$;

$-CO-N(R_3)_2$;

$-CO-C_{1-10}$ alkyl;

$-CO-O-C_{1-10}$ alkyl;

$-N_3$;

-aryl;

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

each R_3 is independently H or C_{1-10} alkyl;

each Y is independently –O– or $–S(O)_{0-2}–$;

n is 0 to 4; and

each R present is independently selected from the group consisting of C_{1-10} alkyl, C_{1-10} alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof.

22. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 1 and a pharmaceutically acceptable carrier.

23. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 10 and a pharmaceutically acceptable carrier.

24. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 17 and a pharmaceutically acceptable carrier.

25. A method of inducing cytokine biosynthesis in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 1 to the animal.

26. The method of claim 25 wherein the cytokine is IFN-α.

27. A method of inducing cytokine biosynthesis in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 10 to the animal.

28. The method of claim 27 wherein the cytokine is IFN-α.

29. A method of treating a viral disease in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 1 to the animal.

30. A method of treating a neoplastic disease in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 1 to the animal.

31. A method of treating a viral disease in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 10 to the animal.

32. A method of treating a neoplastic disease in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 10 to the animal.

33. A method of inducing cytokine biosynthesis in an animal comprising administering a theraputically effective amount of a compound or salt of claim 17 to the animal.

34. The method of claim 33 wherein the cytokine is IFN-α.

35. A method of treating a viral disease in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 17 to the animal.

36. A method of treating a neoplastic disease in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 17 to the animal.

37. A compound of the formula (V):



(V)

wherein: **X** is $-CHR_3-$, $-CHR_3$-alkyl-, or $-CHR_3$-alkenyl-;

$\mathbf{R_1}$ is selected from the group consisting of:

-heteroaryl;

-heterocyclyl;

$-R_4-$ heteroaryl;

$-R_4-$heterocyclyl; and

$-(CH_2)_{1-10}-C\equiv C-R_{10}$;

$\mathbf{R_2}$ is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-heteroaryl;
-heterocyclyl;
-alkyl-Y-alkyl;
-alkyl-Y-alkenyl;
-alkyl-Y-aryl; and
- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:
-OH;
-halogen;
-$N(R_3)_2$;
-$CO\text{-}N(R_3)_2$;
-$CO\text{-}C_{1\text{-}10}$ alkyl;
-$CO\text{-}O\text{-}C_{1\text{-}10}$ alkyl;
-N_3;
-aryl;
-heteroaryl;
-heterocyclyl;
-CO-aryl; and
-CO-heteroaryl;

R_4 is alkyl or alkenyl, which may be interrupted by one or more –O– groups;
each R_3 is independently H or $C_{1\text{-}10}$ alkyl;
R_{10} is heteroaryl or heterocyclyl;
each Y is independently –O– or $-S(O)_{0\text{-}2}$-;
n is 0 to 4; and
each R present is independently selected from the group consisting of $C_{1\text{-}10}$ alkyl, $C_{1\text{-}10}$ alkoxy, hydroxy, halogen and trifluoromethyl;
or a pharmaceutically acceptable salt thereof.

38. A compound of the formula (VI):



(VI)

wherein: **X** is $-CHR_3-$, $-CHR_3$-alkyl-, or $-CHR_3$-alkenyl-;

$\mathbf{R_1}$ is selected from the group consisting of:

-heteroaryl;

-heterocyclyl;

$-R_4-$ heteroaryl;

$-R_4-$heterocyclyl; and

$-(CH_2)_{1-10}-C\equiv C-R_{10}$;

$\mathbf{R_2}$ is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkyl-Y-alkyl;

-alkyl-Y- alkenyl;

-alkyl-Y-aryl; and

- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

-halogen;

$-N(R_3)_2$;

-CO-N(R_3)$_2$;

-CO-$C_{1\text{-}10}$ alkyl;

-CO-O-$C_{1\text{-}10}$ alkyl;

-N_3;

-aryl;

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

$\mathbf{R_4}$ is alkyl or alkenyl, which may be interrupted by one or more –O– groups;

each $\mathbf{R_3}$ is independently H or $C_{1\text{-}10}$ alkyl;

$\mathbf{R_{10}}$ is heteroaryl or heterocyclyl;

each **Y** is independently –O– or –S(O)$_{0\text{-}2}$–;

n is 0 to 4; and

each **R** present is independently selected from the group consisting of $C_{1\text{-}10}$ alkyl, $C_{1\text{-}10}$ alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof.

39. A compound of the formula (VIII):



(VIII)

wherein: **X** is –CHR$_3$–, -CHR$_3$-alkyl-, or –CHR$_3$-alkenyl-;

$\mathbf{R_1}$ is selected from the group consisting of:

-heteroaryl;

-heterocyclyl;

-R_4– heteroaryl; and

-R_4–heterocyclyl;

R_2 is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkyl-Y-alkyl;

-alkyl-Y-alkenyl;

-alkyl-Y-aryl; and

-alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

-halogen;

-$N(R_3)_2$;

-CO-$N(R_3)_2$;

-CO-$C_{1\text{-}10}$ alkyl;

-CO-O-$C_{1\text{-}10}$ alkyl;

-N_3;

-aryl;

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

R_4 is alkyl or alkenyl, which may be interrupted by one or more –O– groups;

each R_3 is independently H or $C_{1\text{-}10}$ alkyl;

each **Y** is independently –O– or $–S(O)_{0\text{-}2}–$;

n is 0 to 4;

each **R** present is independently selected from the group consisting of C_{1-10} alkyl, C_{1-10} alkoxy, hydroxy, halogen and trifluoromethyl; and

R_7 is *tert*-butyl or benzyl;

or a pharmaceutically acceptable salt thereof.

40. A compound of the formula (IX)



(IX)

wherein: **X** is $-CHR_3-$, $-CHR_3$-alkyl-, or $-CHR_3$-alkenyl-;

R_1 is selected from the group consisting of:

-heteroaryl;

-heterocyclyl;

$-R_4-$ heteroaryl; and

$-R_4-$heterocyclyl;

R_2 is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkyl-Y-alkyl;

-alkyl-Y-alkenyl;

-alkyl-Y-aryl; and

- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

-halogen;

$-N(R_3)_2$;

$-CO-N(R_3)_2$;

$-CO-C_{1-10}$ alkyl;

$-CO-O-C_{1-10}$ alkyl;

$-N_3$;

-aryl;

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

$\mathbf{R_4}$ is alkyl or alkenyl, which may be interrupted by one or more –O– groups;

each $\mathbf{R_3}$ is independently H or C_{1-10} alkyl;

each **Y** is independently –O– or $-S(O)_{0-2}-$;

n is 0 to 4; and

each **R** present is independently selected from the group consisting of C_{1-10} alkyl, C_{1-10} alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof.

41. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 18 and a pharmaceutically acceptable carrier.

42. A method of inducing cytokine biosynthesis in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 18 to the animal.

43. The method of claim 42 wherein the cytokine is IFN-α.

44. A method of treating a viral disease in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 18 to the animal.

45. A method of treating a neoplastic disease in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 18 to the animal.

46. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 21 and a pharmaceutically acceptable carrier.

47. A method of inducing cytokine biosynthesis in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 21 to the animal.

48. The method of claim 47 wherein the cytokine is IFN-α.

49. A method of treating a viral disease in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 21 to the animal.

50. A method of treating a neoplastic disease in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 21 to the animal.

51. A compound of the formula (VII):



(VII)

wherein: **Z** is NH_2 or NO_2;

X is $-CHR_3-$, $-CHR_3$-alkyl-, or $-CHR_3$-alkenyl-;

$\mathbf{R_1}$ is selected from the group consisting of:

-heteroaryl;

-heterocyclyl;

-R_4– heteroaryl; and

-R_4–heterocyclyl;

$\mathbf{R_4}$ is alkyl or alkenyl, which may be interrupted by one or more –O– groups;

each $\mathbf{R_3}$ is independently H or $C_{1\text{-}10}$ alkyl;

n is 0 to 4; and

each **R** present is independently selected from the group consisting of $C_{1\text{-}10}$ alkyl, $C_{1\text{-}10}$ alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof.

52. A compound of the formula (XLIV):



(XLIV)

wherein: **X** is –CHR_3-, -CHR_3-alkyl-, or –CHR_3-alkenyl-;

$\mathbf{R_1}$ is selected from the group consisting of:

-heteroaryl;

-heterocyclyl;

-R_4– heteroaryl; and

-R_4–heterocyclyl;

$\mathbf{R_2}$ is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkyl-Y-alkyl;

-alkyl-Y- alkenyl;

-alkyl-Y-aryl; and

- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

-halogen;

-$N(R_3)_2$;

-$CO\text{-}N(R_3)_2$;

-$CO\text{-}C_{1\text{-}10}$ alkyl;

-$CO\text{-}O\text{-}C_{1\text{-}10}$ alkyl;

-N_3;

-aryl;

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

$\mathbf{R_4}$ is alkyl or alkenyl, which may be interrupted by one or more –O– groups;

each $\mathbf{R_3}$ is independently H or $C_{1\text{-}10}$ alkyl;

each **Y** is independently –O– or $-S(O)_{0\text{-}2}-$;

n is 0 to 4; and

each **R** present is independently selected from the group consisting of $C_{1\text{-}10}$ alkyl, $C_{1\text{-}10}$ alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof.